ICCC ImmuCell CEO Stock Option Filing May 20, 2026

Insider trading filings reveal fascinating patterns about executive confidence. When company leaders file stock options, it signals their belief in future performance. ImmuCell Corporation (ICCC) just disclosed a significant stock option grant to its President and CEO. Paul Francis Olivier te Boekhorst received non-qualified stock options worth approximately $149,441. This filing provides insight into executive compensation and long-term incentive structures at the biotech firm.

CEO Stock Option Grant Details

Paul Francis Olivier te Boekhorst, President and CEO of ICCC, received a substantial stock option grant. The filing shows 25,329 non-qualified stock options with a strike price of $5.90 per share. This represents approximately $149,441 in total option value based on the strike price.

The SEC filing was submitted on November 7, 2025. The transaction date listed is September 16, 2028, which appears to be a future-dated grant or reporting adjustment. Non-qualified stock options give executives the right to purchase shares at a predetermined price.

What Form 3 Filings Mean for Investors

Form 3 is an initial ownership filing required when insiders first acquire securities. This particular filing documents the CEO’s stock option holdings. It establishes a baseline record for tracking future transactions and changes in ownership.

Form 3 filings are critical for transparency. They show what executives hold and at what price. Investors use these filings to understand executive stake in the company. ImmuCell’s CEO now has significant upside exposure if the stock price rises above $5.90.

Non-Qualified Stock Options Explained

Non-qualified stock options (NSOs) differ from incentive stock options in tax treatment. NSOs are taxed as ordinary income when exercised. The difference between strike price and market price becomes taxable compensation.

For the CEO, these 25,329 options represent long-term incentive alignment. If ImmuCell stock rises significantly above $5.90, the options become valuable. This structure encourages executives to drive shareholder value. Meyka AI rates ICCC a grade of B, reflecting solid fundamentals in the biotech sector.

Executive Compensation and Market Position

ImmuCell’s market cap sits at $92.3 million, making this option grant meaningful relative to company size. The CEO’s compensation package ties directly to stock performance. This alignment is positive for minority shareholders seeking management accountability.

The $5.90 strike price reflects the company’s valuation at grant time. If the stock appreciates, the CEO benefits alongside all shareholders. This structure is standard in biotech, where long-term value creation drives executive motivation.

Final Thoughts

ImmuCell’s CEO received a substantial non-qualified stock option grant worth $149,441, representing 25,329 shares at a $5.90 strike price. This Form 3 filing establishes the executive’s initial ownership position and signals management confidence in the company’s future. The option structure aligns CEO interests with shareholder returns, a positive indicator for long-term value creation at the $92.3 million market cap biotech firm.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Insider trading data is sourced from public SEC filings. This is not financial advice. Always conduct your own research and consult a licensed financial advisor before making investment decisions.